PROSTAGLANDIN EXCRETION IN PREECLAMPSIA

前列腺素代谢紊乱目前被认为是一种 先兆子痫发病机制的主要机制。 最 然而，以前对这一理论的研究只包括那些 已经出现了临床上明显的疾病。 为了研究 前列腺素异常是否先于先兆子痫发作， 我们设计了一个巢式病例对照研究， 前瞻性收集早在妊娠13周的妇女 参与NICHD钙预防先兆子痫试验 （CPEP）。 在这项研究中，我们将比较 子痫前期妇女诊断前前列腺素和血栓素水平 子痫前期与正常妊娠妇女在相当的 胎龄 因为CPEP试验中一半的女性 每天服用两克口服钙，我们也可以检查 口服钙补充剂对这些排泄的影响 前列腺素代谢物。

A disturbance of prostaglandin metabolism is currently believed to be one of the major mechanisms in the pathogenesis of preeclampsia. Most previous studies of this theory, however, have included only women who had already developed clinically overt disease. In order to investigate whether prostaglandin abnormalities precede the onset of preeclampsia, we have designed a nested case-control study using stored urine specimens prospectively collected as early as thirteen weeks gestation from women participating in the NICHD Trial of Calcium to Prevent Preeclampsia (CPEP). In this study, we will compare the urinary excretion of prostaglandin and thromboxane in preeclampsic women before the diagnosis of preeclampsia to that in normal pregnant women at comparable gestational ages. Because half of the women in the CPEP trial will be taking two grams of oral calcium daily, we will also be able to examine the effect of oral calcium supplementation on the excretion of these prostaglandin metabolites.